Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSCB7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $33,432
Award facts
- Contract value 100% obligated
- $33,431.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $33,431.92 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. The delivery order was issued on December 16, 2025, with an ultimate completion date of January 8, 2026, and carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) designated SPE2DR, which was established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative with a $499.999 billion ceiling and a completion date of December 31, 2036.
The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors to supply the comprehensive pharmaceutical needs of Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's assignment under this contract authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for branded and generic prescription medications, over-the-counter drugs, biologics, and medical consumables. The contractor's established performance across numerous prior delivery orders for specialized pharmaceutical products including oncology treatments, immunosuppressants, and biologics demonstrates its capability to fulfill the diverse medical supply requirements of the federal military medical system. No subcontractors were identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FSCB7?
SPE2DR26FSCB7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 16, 2025.
How much is contract SPE2DR26FSCB7 worth?
The government has obligated $33,432 on SPE2DR26FSCB7.
Is contract SPE2DR26FSCB7 an order under another contract?
Yes. SPE2DR26FSCB7 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCB7 competed?
The extent of competition for SPE2DR26FSCB7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award